(0.07%) 5 521.00 points
(0.11%) 39 886 points
(0.16%) 19 782 points
(0.01%) $81.64
(0.50%) $2.83
(-0.33%) $2 336.70
(-0.03%) $29.52
(0.30%) $1 004.80
(0.01%) $0.932
(0.01%) $10.54
(-0.01%) $0.788
(-0.57%) $87.50
1.37% $ 11.86
Live Chart Being Loaded With Signals
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye...
Stats | |
---|---|
Dzisiejszy wolumen | 59 065 |
Średni wolumen | 37 183 |
Kapitalizacja rynkowa | 494.56M |
EPS | $-0.440 ( Q1 | 2024-05-08 ) |
Następna data zysków | ( $-0.410 ) 2024-09-03 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
65.89 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0450 (0.38%) |
Oculis Holding AG Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Oculis Holding AG Finanse
Annual | 2023 |
Przychody: | $883 000 |
Zysk brutto: | $-28.36M (-3 212.23 %) |
EPS: | $-2.97 |
FY | 2023 |
Przychody: | $883 000 |
Zysk brutto: | $-28.36M (-3 212.23 %) |
EPS: | $-2.97 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $0 (0.00 %) |
EPS: | $-1.180 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Oculis Holding AG
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company\'s lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej